Oligonucleotides Targeted Against a Junction Oncogene Are Made Efficient by Nanotechnologies View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2003-10

AUTHORS

Andrei Maksimenko, Claude Malvy, Gregory Lambert, Jean-Rémy Bertrand, Elias Fattal, Jean Maccario, Patrick Couvreur

ABSTRACT

PURPOSE: Antisense oligonucleotides (AON) against junction EWS-Fli-1 oncogene (which is responsible for the Ewing Sarcoma) are particularly interesting for targeting chromosomal translocations that are only found in tumor cells. However, these AON have proved in the past to be ineffective in vivo because of their susceptibility to degradation and their poor intracellular penetration. The aim of this study was to improve the delivery of these molecules through the use of nanotechnologies. METHOD: Two different AONs, and their controls, both targeted against the junction area of the fusion gene EWS-Fli-1 were used. Nanocapsules were employed to deliver a phosphorothioate AON and its control. The nanospheres were used to deliver a chimeric phosphorothioate, phosphodiester AON, with 5 additional bases in 5' which allow this AON to be structured with a loop. These formulations were injected intratumorally to nude mice bearing the experimental EWS-Fli-1 tumor. The tumour volume was estimated during the experiments by two perpendicular measurements length (a) and width (b) of the tumour and was calculated as ab(2)/2. Northern blot analysis was also performed after removing the tumors 24 h after the treatment with a single dose of AON either free or associated with nanotechnologies. RESULTS: This study shows for the first time that AON against EWS-Fli-1 oncogene may inhibit with high specificity the growth of an EWS-Fli-1 dependent tumor grafted to nude mice provided they are delivered by nanocapsules or nanospheres. In this experience, the antisense effect was confirmed by the specific down regulation of EWS-Fli-1 mRNA. CONCLUSION: Thus, both nanocapsules and nanospheres may be considered as promising systems for AON delivery in vivo. More... »

PAGES

1565-1567

Identifiers

URI

http://scigraph.springernature.com/pub.10.1023/a:1026122914852

DOI

http://dx.doi.org/10.1023/a:1026122914852

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1005136437

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/14620508


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Animals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Blotting, Northern", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Capsules", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Delivery Systems", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Gene Transfer Techniques", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mice", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mice, Nude", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Nanotechnology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Oligonucleotides, Antisense", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Oncogene Proteins, Fusion", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Particle Size", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proto-Oncogene Protein c-fli-1", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "RNA-Binding Protein EWS", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sarcoma, Ewing", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Transcription Factors", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Onxeo (France)", 
          "id": "https://www.grid.ac/institutes/grid.432920.e", 
          "name": [
            "Institut Gustave Roussy, CNRS UMR 1582, 39 rue Camille Desmoulins, 94805, Villejuif cedex, France", 
            "BioAlliance Pharma, 59, Boulevard du G\u00e9n\u00e9ral Martial Valin, 75015, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Maksimenko", 
        "givenName": "Andrei", 
        "id": "sg:person.01340771606.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01340771606.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut Gustave Roussy", 
          "id": "https://www.grid.ac/institutes/grid.14925.3b", 
          "name": [
            "Institut Gustave Roussy, CNRS UMR 1582, 39 rue Camille Desmoulins, 94805, Villejuif cedex, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Malvy", 
        "givenName": "Claude", 
        "id": "sg:person.01037610656.22", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01037610656.22"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Novagali SAS, 4 rue Pierre Fontaine, 91000, Evry, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lambert", 
        "givenName": "Gregory", 
        "id": "sg:person.01266265435.77", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01266265435.77"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut Gustave Roussy", 
          "id": "https://www.grid.ac/institutes/grid.14925.3b", 
          "name": [
            "Institut Gustave Roussy, CNRS UMR 1582, 39 rue Camille Desmoulins, 94805, Villejuif cedex, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bertrand", 
        "givenName": "Jean-R\u00e9my", 
        "id": "sg:person.010236660502.77", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010236660502.77"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut Gustave Roussy", 
          "id": "https://www.grid.ac/institutes/grid.14925.3b", 
          "name": [
            "Institut Gustave Roussy, CNRS UMR 1582, 39 rue Camille Desmoulins, 94805, Villejuif cedex, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fattal", 
        "givenName": "Elias", 
        "id": "sg:person.01146450602.87", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01146450602.87"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Paris-Sud", 
          "id": "https://www.grid.ac/institutes/grid.5842.b", 
          "name": [
            "INSERM, Universit\u00e9 Paris-Sud, 94805, Villejuif, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Maccario", 
        "givenName": "Jean", 
        "id": "sg:person.0761332540.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0761332540.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Facult\u00e9 de Pharmacie, Chatenay-, CNRS UMR 8612, Malabry, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Couvreur", 
        "givenName": "Patrick", 
        "id": "sg:person.0760312615.72", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0760312615.72"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1172/jci119152", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014854312"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1006/bbrc.2000.3963", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017328614"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/a:1007582332491", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032461777", 
          "https://doi.org/10.1023/a:1007582332491"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/a:1015871809313", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035402570", 
          "https://doi.org/10.1023/a:1015871809313"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/07328319908044865", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041217538"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2003-10", 
    "datePublishedReg": "2003-10-01", 
    "description": "PURPOSE: Antisense oligonucleotides (AON) against junction EWS-Fli-1 oncogene (which is responsible for the Ewing Sarcoma) are particularly interesting for targeting chromosomal translocations that are only found in tumor cells. However, these AON have proved in the past to be ineffective in vivo because of their susceptibility to degradation and their poor intracellular penetration. The aim of this study was to improve the delivery of these molecules through the use of nanotechnologies.\nMETHOD: Two different AONs, and their controls, both targeted against the junction area of the fusion gene EWS-Fli-1 were used. Nanocapsules were employed to deliver a phosphorothioate AON and its control. The nanospheres were used to deliver a chimeric phosphorothioate, phosphodiester AON, with 5 additional bases in 5' which allow this AON to be structured with a loop. These formulations were injected intratumorally to nude mice bearing the experimental EWS-Fli-1 tumor. The tumour volume was estimated during the experiments by two perpendicular measurements length (a) and width (b) of the tumour and was calculated as ab(2)/2. Northern blot analysis was also performed after removing the tumors 24 h after the treatment with a single dose of AON either free or associated with nanotechnologies.\nRESULTS: This study shows for the first time that AON against EWS-Fli-1 oncogene may inhibit with high specificity the growth of an EWS-Fli-1 dependent tumor grafted to nude mice provided they are delivered by nanocapsules or nanospheres. In this experience, the antisense effect was confirmed by the specific down regulation of EWS-Fli-1 mRNA.\nCONCLUSION: Thus, both nanocapsules and nanospheres may be considered as promising systems for AON delivery in vivo.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1023/a:1026122914852", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094644", 
        "issn": [
          "0724-8741", 
          "1573-904X"
        ], 
        "name": "Pharmaceutical Research", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "10", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "20"
      }
    ], 
    "name": "Oligonucleotides Targeted Against a Junction Oncogene Are Made Efficient by Nanotechnologies", 
    "pagination": "1565-1567", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "1878dcf15c687a6ce3c8c3f46eba86396f711d57782b7c06475f161adc935f99"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "14620508"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8406521"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1023/a:1026122914852"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1005136437"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1023/a:1026122914852", 
      "https://app.dimensions.ai/details/publication/pub.1005136437"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T13:13", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8659_00000503.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1023%2FA%3A1026122914852"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1023/a:1026122914852'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1023/a:1026122914852'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1023/a:1026122914852'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1023/a:1026122914852'


 

This table displays all metadata directly associated to this object as RDF triples.

207 TRIPLES      21 PREDICATES      51 URIs      38 LITERALS      26 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1023/a:1026122914852 schema:about N1b40515da53e4b8b9e85152c0587ce6b
2 N246ffd4a3cce494b94cdfcd11a03ceeb
3 N2bc82a8b09d64239ac2dbac3cbbc7631
4 N320d15f7b93741619bb145956e7e26ec
5 N3de02fe509ee4529ba890666e5ad7ff9
6 N4788fa59055b461b8adaea5e52c949bd
7 N48e635aab0074e37a02e03261ca87ba2
8 N6220535a24c5454e9c74508bb34419ed
9 N681b30b5cc5d4962af304610726fbba9
10 N74ff14906b8c4625b1a2b0fc50cf1d9f
11 N95faed06bed64c1c9ee3e894b8fb1a17
12 Nd39237d99efb4d339cf3f1fef9237f8d
13 Nd9726689875a48838062c697865c9331
14 Nec5b5d8edf934911a11d00955d9dadf8
15 Nf286dccfcb4943e39ee955d2f2cdf3d4
16 Nfbaf4b544ea44d0db57ed280b258578f
17 Nfca0cd115d41487b89982d7a61a71be1
18 anzsrc-for:11
19 anzsrc-for:1112
20 schema:author Na9d372eda4854c61b9302270ac4c6fa9
21 schema:citation sg:pub.10.1023/a:1007582332491
22 sg:pub.10.1023/a:1015871809313
23 https://doi.org/10.1006/bbrc.2000.3963
24 https://doi.org/10.1080/07328319908044865
25 https://doi.org/10.1172/jci119152
26 schema:datePublished 2003-10
27 schema:datePublishedReg 2003-10-01
28 schema:description PURPOSE: Antisense oligonucleotides (AON) against junction EWS-Fli-1 oncogene (which is responsible for the Ewing Sarcoma) are particularly interesting for targeting chromosomal translocations that are only found in tumor cells. However, these AON have proved in the past to be ineffective in vivo because of their susceptibility to degradation and their poor intracellular penetration. The aim of this study was to improve the delivery of these molecules through the use of nanotechnologies. METHOD: Two different AONs, and their controls, both targeted against the junction area of the fusion gene EWS-Fli-1 were used. Nanocapsules were employed to deliver a phosphorothioate AON and its control. The nanospheres were used to deliver a chimeric phosphorothioate, phosphodiester AON, with 5 additional bases in 5' which allow this AON to be structured with a loop. These formulations were injected intratumorally to nude mice bearing the experimental EWS-Fli-1 tumor. The tumour volume was estimated during the experiments by two perpendicular measurements length (a) and width (b) of the tumour and was calculated as ab(2)/2. Northern blot analysis was also performed after removing the tumors 24 h after the treatment with a single dose of AON either free or associated with nanotechnologies. RESULTS: This study shows for the first time that AON against EWS-Fli-1 oncogene may inhibit with high specificity the growth of an EWS-Fli-1 dependent tumor grafted to nude mice provided they are delivered by nanocapsules or nanospheres. In this experience, the antisense effect was confirmed by the specific down regulation of EWS-Fli-1 mRNA. CONCLUSION: Thus, both nanocapsules and nanospheres may be considered as promising systems for AON delivery in vivo.
29 schema:genre research_article
30 schema:inLanguage en
31 schema:isAccessibleForFree false
32 schema:isPartOf N14edfef373284034b28e4547e4be4121
33 N1fcbbbbe63a94e9d988fea69f0541e05
34 sg:journal.1094644
35 schema:name Oligonucleotides Targeted Against a Junction Oncogene Are Made Efficient by Nanotechnologies
36 schema:pagination 1565-1567
37 schema:productId N4f3ce85988c24619b899aaf5b78b3818
38 N79a4bc94b1d84e04a03b490fa30081c3
39 Nbff367a24bfa4ed3a4044a6174c27a24
40 Ncc74a17eee2243a5953b9614b0f907a4
41 Nf0d8b881ae1244b3832f9e6af60bd9d7
42 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005136437
43 https://doi.org/10.1023/a:1026122914852
44 schema:sdDatePublished 2019-04-10T13:13
45 schema:sdLicense https://scigraph.springernature.com/explorer/license/
46 schema:sdPublisher Nb683eafdfbde4fbd85a54e7c63684722
47 schema:url http://link.springer.com/10.1023%2FA%3A1026122914852
48 sgo:license sg:explorer/license/
49 sgo:sdDataset articles
50 rdf:type schema:ScholarlyArticle
51 N14edfef373284034b28e4547e4be4121 schema:volumeNumber 20
52 rdf:type schema:PublicationVolume
53 N15640a6499164612b527b8ece85fb927 rdf:first sg:person.01146450602.87
54 rdf:rest Nc639380c93464cb7b214d7432e5cc377
55 N1b40515da53e4b8b9e85152c0587ce6b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
56 schema:name Mice, Nude
57 rdf:type schema:DefinedTerm
58 N1fcbbbbe63a94e9d988fea69f0541e05 schema:issueNumber 10
59 rdf:type schema:PublicationIssue
60 N246ffd4a3cce494b94cdfcd11a03ceeb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
61 schema:name Animals
62 rdf:type schema:DefinedTerm
63 N2bc82a8b09d64239ac2dbac3cbbc7631 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
64 schema:name RNA-Binding Protein EWS
65 rdf:type schema:DefinedTerm
66 N320d15f7b93741619bb145956e7e26ec schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
67 schema:name Oligonucleotides, Antisense
68 rdf:type schema:DefinedTerm
69 N3de02fe509ee4529ba890666e5ad7ff9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
70 schema:name Capsules
71 rdf:type schema:DefinedTerm
72 N4788fa59055b461b8adaea5e52c949bd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
73 schema:name Blotting, Northern
74 rdf:type schema:DefinedTerm
75 N48e635aab0074e37a02e03261ca87ba2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
76 schema:name Drug Delivery Systems
77 rdf:type schema:DefinedTerm
78 N4f3ce85988c24619b899aaf5b78b3818 schema:name dimensions_id
79 schema:value pub.1005136437
80 rdf:type schema:PropertyValue
81 N52292e8de40c48cc9930aecae30ea49e rdf:first sg:person.01266265435.77
82 rdf:rest Nf53593d87497439c8ed5736582a83ff8
83 N6220535a24c5454e9c74508bb34419ed schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
84 schema:name Gene Transfer Techniques
85 rdf:type schema:DefinedTerm
86 N681b30b5cc5d4962af304610726fbba9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
87 schema:name Oncogene Proteins, Fusion
88 rdf:type schema:DefinedTerm
89 N69771c4856294b07a11573c5ac6f4f23 schema:name Faculté de Pharmacie, Chatenay-, CNRS UMR 8612, Malabry, France
90 rdf:type schema:Organization
91 N74ff14906b8c4625b1a2b0fc50cf1d9f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
92 schema:name Particle Size
93 rdf:type schema:DefinedTerm
94 N79a4bc94b1d84e04a03b490fa30081c3 schema:name nlm_unique_id
95 schema:value 8406521
96 rdf:type schema:PropertyValue
97 N81daeb0521064061b3a6ebaf4698f34e rdf:first sg:person.0760312615.72
98 rdf:rest rdf:nil
99 N8b37e04a08b343c0b7867462e71269e2 rdf:first sg:person.01037610656.22
100 rdf:rest N52292e8de40c48cc9930aecae30ea49e
101 N95faed06bed64c1c9ee3e894b8fb1a17 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Antineoplastic Agents
103 rdf:type schema:DefinedTerm
104 Na9d372eda4854c61b9302270ac4c6fa9 rdf:first sg:person.01340771606.27
105 rdf:rest N8b37e04a08b343c0b7867462e71269e2
106 Nb683eafdfbde4fbd85a54e7c63684722 schema:name Springer Nature - SN SciGraph project
107 rdf:type schema:Organization
108 Nbff367a24bfa4ed3a4044a6174c27a24 schema:name pubmed_id
109 schema:value 14620508
110 rdf:type schema:PropertyValue
111 Nc639380c93464cb7b214d7432e5cc377 rdf:first sg:person.0761332540.51
112 rdf:rest N81daeb0521064061b3a6ebaf4698f34e
113 Ncc74a17eee2243a5953b9614b0f907a4 schema:name readcube_id
114 schema:value 1878dcf15c687a6ce3c8c3f46eba86396f711d57782b7c06475f161adc935f99
115 rdf:type schema:PropertyValue
116 Nd39237d99efb4d339cf3f1fef9237f8d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Proto-Oncogene Protein c-fli-1
118 rdf:type schema:DefinedTerm
119 Nd9726689875a48838062c697865c9331 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Sarcoma, Ewing
121 rdf:type schema:DefinedTerm
122 Ne6db5220c29841e28509ca6bfe894cea schema:name Novagali SAS, 4 rue Pierre Fontaine, 91000, Evry, France
123 rdf:type schema:Organization
124 Nec5b5d8edf934911a11d00955d9dadf8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Mice
126 rdf:type schema:DefinedTerm
127 Nf0d8b881ae1244b3832f9e6af60bd9d7 schema:name doi
128 schema:value 10.1023/a:1026122914852
129 rdf:type schema:PropertyValue
130 Nf286dccfcb4943e39ee955d2f2cdf3d4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Transcription Factors
132 rdf:type schema:DefinedTerm
133 Nf53593d87497439c8ed5736582a83ff8 rdf:first sg:person.010236660502.77
134 rdf:rest N15640a6499164612b527b8ece85fb927
135 Nfbaf4b544ea44d0db57ed280b258578f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Nanotechnology
137 rdf:type schema:DefinedTerm
138 Nfca0cd115d41487b89982d7a61a71be1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Bone Neoplasms
140 rdf:type schema:DefinedTerm
141 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
142 schema:name Medical and Health Sciences
143 rdf:type schema:DefinedTerm
144 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
145 schema:name Oncology and Carcinogenesis
146 rdf:type schema:DefinedTerm
147 sg:journal.1094644 schema:issn 0724-8741
148 1573-904X
149 schema:name Pharmaceutical Research
150 rdf:type schema:Periodical
151 sg:person.010236660502.77 schema:affiliation https://www.grid.ac/institutes/grid.14925.3b
152 schema:familyName Bertrand
153 schema:givenName Jean-Rémy
154 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010236660502.77
155 rdf:type schema:Person
156 sg:person.01037610656.22 schema:affiliation https://www.grid.ac/institutes/grid.14925.3b
157 schema:familyName Malvy
158 schema:givenName Claude
159 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01037610656.22
160 rdf:type schema:Person
161 sg:person.01146450602.87 schema:affiliation https://www.grid.ac/institutes/grid.14925.3b
162 schema:familyName Fattal
163 schema:givenName Elias
164 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01146450602.87
165 rdf:type schema:Person
166 sg:person.01266265435.77 schema:affiliation Ne6db5220c29841e28509ca6bfe894cea
167 schema:familyName Lambert
168 schema:givenName Gregory
169 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01266265435.77
170 rdf:type schema:Person
171 sg:person.01340771606.27 schema:affiliation https://www.grid.ac/institutes/grid.432920.e
172 schema:familyName Maksimenko
173 schema:givenName Andrei
174 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01340771606.27
175 rdf:type schema:Person
176 sg:person.0760312615.72 schema:affiliation N69771c4856294b07a11573c5ac6f4f23
177 schema:familyName Couvreur
178 schema:givenName Patrick
179 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0760312615.72
180 rdf:type schema:Person
181 sg:person.0761332540.51 schema:affiliation https://www.grid.ac/institutes/grid.5842.b
182 schema:familyName Maccario
183 schema:givenName Jean
184 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0761332540.51
185 rdf:type schema:Person
186 sg:pub.10.1023/a:1007582332491 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032461777
187 https://doi.org/10.1023/a:1007582332491
188 rdf:type schema:CreativeWork
189 sg:pub.10.1023/a:1015871809313 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035402570
190 https://doi.org/10.1023/a:1015871809313
191 rdf:type schema:CreativeWork
192 https://doi.org/10.1006/bbrc.2000.3963 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017328614
193 rdf:type schema:CreativeWork
194 https://doi.org/10.1080/07328319908044865 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041217538
195 rdf:type schema:CreativeWork
196 https://doi.org/10.1172/jci119152 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014854312
197 rdf:type schema:CreativeWork
198 https://www.grid.ac/institutes/grid.14925.3b schema:alternateName Institut Gustave Roussy
199 schema:name Institut Gustave Roussy, CNRS UMR 1582, 39 rue Camille Desmoulins, 94805, Villejuif cedex, France
200 rdf:type schema:Organization
201 https://www.grid.ac/institutes/grid.432920.e schema:alternateName Onxeo (France)
202 schema:name BioAlliance Pharma, 59, Boulevard du Général Martial Valin, 75015, Paris, France
203 Institut Gustave Roussy, CNRS UMR 1582, 39 rue Camille Desmoulins, 94805, Villejuif cedex, France
204 rdf:type schema:Organization
205 https://www.grid.ac/institutes/grid.5842.b schema:alternateName University of Paris-Sud
206 schema:name INSERM, Université Paris-Sud, 94805, Villejuif, France
207 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...